Supported by Boehringer Ingelheim Pharmaceuticals, Inc. and created together with the Pulmonary Fibrosis Foundation and the Coalition for Pulmonary Fibrosis, the documentary aims at increasing public awareness and understanding of idiopathic pulmonary fibrosis (IPF). The documentary can also be viewed at www.everybreathcountsfilm.com.
Currently without any FDA-approved treatments, IPF is a rare, progressive, and fatal lung disease, affecting 132,000 Americans. Marked by an increasing difficulty in breathing and a reduced capacity of the lungs to supply oxygen to the bloodstream, many patients succumb to the disease within 3 to 5 years after diagnosis.
Tunde Otulana, M.D., senior vice president, Clinical Development and Medical Affairs at Boehringer Ingelheim Pharmaceuticals, Inc. noted, “Every Breath Counts is an authentic and emotional depiction of the impact IPF has on the lives of patients and their caregivers. For 50 years, Boehringer Ingelheim has been a leader in respiratory research, patient support and disease education, and support of opportunities such as this documentary enable us to further our commitment to supporting the IPF community.”
The challenges faced by IPF patients, their families, and caregivers, and with comments from leading pulmonologists, Every Breath Counts focuses on increasing the public awareness of this devastating disease.
Erica Herzog, M.D., associate professor of medicine and director of the ILD Center of Excellence at Yale Fibrosis Program, Yale School of Medicine featuring in Every Breath Counts said, “This is an encouraging time for those living with or affected by this devastating disease, as the understanding and research of this disease continues to advance. Additionally, programs like the Every Breath Counts documentary and the FDA’s public meeting on IPF on September 26th, are truly giving patients a voice to share their stories and the impact of this disease to help raise awareness and understanding.”